Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients

Clinical and Experimental Medicine

Volumn 2, Issue 4, 2003, Pages 185-191

  Schneider, J ^a   Peltri, G ^b   Bitterlich, N ^b   Philipp, M ^a   Velcovsky, H G ^a   Morr, H ^c   Katz, N ^a   Eigenbrodt, E ^d  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b pe Diagnostik GmbH   (Germany)

^c Pneumologische Klin Waldhof E   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Fuzzy logic; Small cell lung cancer; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; TUMOR M2 PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; LUNG SMALL CELL CANCER; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; CARCINOMA, SMALL CELL; FEMALE; FUZZY LOGIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 12244280804     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s102380300005     Document Type: Article

References (42)

1. Akoun GM, Scarna HM, Milleron BJ, Benechou MP, Herman DP (1985) Serum neuron-specific enolase: a marker for disease extent and response to therapy for small call lung cancer. Chest 87:39-43
2. Carney DN, Marangos PJ, Ihde DC, Bunn PA, Cohen MH, Minna JD (1982) Serum neuron-specific enolase: a marker for disease extent and response to therapy of small cell lung cancer. Lancet I:583-585
3. Moody TW, Pert CB, Gazdar F, Carney DN, Minna JD (1981) High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 214:1246-1248
4. Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, Makimoto T, Ishihara S, Saito R, Mori M (1999) Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 57:143-148
5. Maruno K, Yamaguchi K, Abe K, Suzuki M, Saijo N, Moshima Y, Yanaihara N, Shimosato Y (1989) Immunoreactive gastrin-releasing peptide as a specific marker in patients with small cell lung carcinoma. Cancer Res 49:629-632
6. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K (1999) Pro-gastrin-releasing peptide (ProGRP) - a useful marker in small cell lung carcinomas. Anticancer Res 19:2673-2678
7. Shijubo N, Hirasawa M, Sasaki H, Igarashi T, Fujita A, Kodama T, Yamaguchi K, Abe S (1996) Elevated pro-gastrin-releasing peptide (31-98) concentrations in pleural effusions due to small-cell lung carcinoma. Respiration 63:106-110
8. Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, Otsubo K, Miyake Y, Kodama T (1995) Enzyme-linked immunoabsorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 86:698-705
9. Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N (2003) Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytoceratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res (in press)
10. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R (1992) Double role for pyruvate kinase type M2 in expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 3:91-115
11. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E (2002) Tumor M2-pyruvate-kinase in lung cancer patients - immunohistochemical detection and disease monitoring. Anticancer Res 22:311-318
12. Goslin RH, Skarin AT, Zamchek N (1981) Carcino-embryonic antigen: a useful monitor of therapy of small cell lung cancer. J Am Med Assoc 246:2173-2176
13. Ebert W, Hoppe M, Muley T, Drings P (1997) Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-TP, CEA and NSE. Anticancer Res 17:2875-2878
14. Spiro SG (1988) Prognosis and end results. In: Hoogastraten B, Addis BJ, Hansen HH, Martini N, Spiro SG (eds) Lung tumors. Springer-Verlag, Berlin Heidelbergh New York, pp 163-166
15. Keller T, Bitterlich N, Hilfenhaus S, Bigl H, Löser T, Leonhardt P (1998) Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles. J Cancer Res Clin Oncol 124:565-574
16. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N, Eigenbrodt E (2002) Fuzzy logic-based tumour marker-profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 7:145-151
17. World Health Organization (1981) Histological classification of lung tumors. WHO, Geneva
18. World Health Organization (1979) WHO handbook of reporting results of cancer treatment. World Health Organization offset publication no. 48, Geneva
19. Zadeh LA (1965) Fuzzy sets. Information Control 8:35-40
20. Zimmermann HJ (1991) Fuzzy set theory and its application, 2nd edn. Kluwer, Boston
21. Bocklisch SF, Bitterlich N (1994) Fuzzy pattern classification- methodology and application. In: Kruse R, Gebhard J, Palm R (eds) Fuzzy systems in computer science. Vieweg, Wiesbaden
22. Schmidt L, Uhde C, Huber RM (2000) Nachsorge bei maligne Tumoren. In: Schalhorn A (ed) Manual Tumoren der Lunge und des Mediastinums. Zuckschwerdt Verlag, Munich, pp 105-113
23. Johnson DH, Marangos PJ, Forbes JT, Hainsworth JD, Van Welch R, Hande KR, Greco FA (1984) Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Res 44:5409-5414
24. Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, Yamaguchi K (1995) Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small cell lung carcinoma: development and evaluation. Clin Chem 41:537-543
25. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M (1996) Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 73:1227-1232
26. Miyake Y, Kodama T, Yamaguchi K (1994) Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 54:2136-2140
27. Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N (1997) Serum levels of progastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 3:123-127
28. Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R, Kodama T (2000) Significance of serum pro-gastrin-releasing as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 27:159-167
29. Fischbach W, Schwarz-Wallrauch C, Jany B (1989) Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small call lung cancer. Cancer 63:1143-1149
30. Bonner JA, Sloan JA, Rowland KM, Klee GG, Kugler JW, Maillaird JA, Wiesenfeld M, Krook JE, Maksymiuk AW, Shaw EG, Marks RS, Perez EA (2000) Significance of neuron specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 6:597-601
31. Stieber P, Dienemann H, Schmitt UM, Reinmiedl J, Hasholzner U, Reiter W, Hofmann K, Schalhorn V, Yamaguchi K (1997) Pro-gastrin-releasing peptide (ProGRP), a new marker in small cell lung carcinomas. J Lab Med 21:336-344
32. Gasser RW, Denz H, Huber H (1989) Tumormarker beim Bronchialkarzinom. Wien Klin Wochenschr 101:476-479
33. Ebert W, Muley T (1999) Cyfra 21-1 in the follow-up of inoperable non small cell lung cancer patients treated with chemotherapy. Anticancer Res 19:2669-2672
34. Ho YJ, Hsieh JF, Tasi SC, Lee JK, Kao CH (2000) Tissue polypeptide specific antigen and squamous cell carcinoma antigen for early prediction of recurrence in lung squamous cell carcinoma. Lung 178:75-80
35. Splinter TA, Cooper EH, Kho GS, Oosterom R, Peake MD (1987) Neuron specific enolase as a guide to the treatment of small cell lung cancer. Eur J Cancer Clin Oncol 23:171-176
36. Pujol JL, Boher JM, Grenier J, Quantin X (2001) Cyfra 21-1, neuron specific enolase and prognosis of non small cell lung cancer: prospective study in 621 patients. Lung Cancer 31:221-231
37. Pinson P, Joos G, Watripont P, Brusselle G, Pauwels R (1997) Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small cell lung cancer. Respiration 64:102-107
38. Jorgensen LG, Osterlind K, Hansen HH, Cooper EH (1994) Serum neuron specific enolase (S-NSE) in progressive small cell lung cancer (SCLC). Br J Cancer 70:759-761
39. Giovanella L, Ceriani L, Bandera M, Beghe B, Roncari G (1995) Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21-1 in lung cancer. Int J Biol Markers 10:156-160
40. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C (1995) CEA, CYFRA 21-1 and SCC in non-small cell lung cancer. Lung Cancer 13:169-176
41. Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K, Okura H (1996) Preliminary evaluation of the new tumour marker CYFRA 21-1 in lung cancer patients. Jpn J Clin Oncol 24:263-268
42. Kohno N, Hirasawa Y, Kondo K, Fujioka S, Fujino S, Abe M, Yokoyama A, Hiwada K, Watanabe K, Nishimura J (1997) Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma. Cancer Detect Prev 21:124-128